Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Audentes Therapeutics Inc (BOLD)

37.92 -0.42 (-1.1%)

05-22 16:00

Open:

37.76

Pre. Close:

38.34

High:

38.69

Low:

36.66

Volume:

594,190

Market Cap:

1393M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

38.747 - 38.942

38.942 - 39.103

Low:

36.224 - 36.424

36.424 - 36.588

Close:

37.619 - 37.941

37.941 - 38.206

Technical analysis  (as of: 2018-05-22 4:37:09 PM)

Overall:

      

Stoxline posted a BUY today, same as yesterday. This stock seems to continue bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, upward move is expected.

Target:

Six months: 49.77     One year: 58.13

Support:

Support1: 24.19    Support2: 12.81

Resistance:

Resistance1: 42.61    Resistance2: 49.77

Pivot:

34.52

Moving Averages:

MA(5): 32.88     MA(20): 35.16

MA(100): 34.25     MA(250): 27.56

MACD:

MACD(12,26): -0.52     Signal(12,26,9): -0.26

%K %D:

%K(14,3): 56.64     %D(3): 53.55

RSI:

RSI(14): 52.73

52-Week:

High: 42.61  Low: 13.898  Change(%): 126.1

Average Vol(K):

3-Month: 40796  10-Days 68244

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
BOLD has closed below upper band by 36.2%. Bollinger Bands are 192.2% wider than normal. The large width of the bands suggest high volatility as compared to BOLD's normal range. The bands have been in this wide range for 2 bars. This is a sign that the current trend might continue.

Headline News

2018-05-17T12:00:00-04:00
Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data

2018-05-16T12:15:20-04:00
Audentes reports positive results from study of AT132 in XLMTM; shares up 7%

2018-05-16T11:31:47-04:00
Bluebird Bio: Gene Therapy Best In Class

2018-05-16T11:30:00-04:00
Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy

2018-05-14T15:12:28-04:00
Genomic Medicine: Catch The Gene Therapy Wave

2018-05-12T06:15:11-04:00
Audentes Therapeutics: Key Program Updates

2018-05-11T12:02:27-04:00
Key events next week - healthcare

2018-05-09T23:03:10-04:00
Audentes Therapeutics' (BOLD) CEO Matt Patterson on Q1 2018 Results - Earnings Call Transcript

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

NA

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

36.74

Shares Float (M)

36.22

% Held by Insiders

1.40

% Held by Institutions

82.50

Shares Short (K)

2275

Shares Short Prior Month (K)

713

Stock Financials

EPS

-3.310

EPS Est. Current Year

-3.500

EPS Est. Next Year

-3.630

EPS Est. Next Quarter

-0.900

Forward EPS

-3.461

Book Value (p.s.)

7.890

PEG Ratio

-2.58

Profit Margin

Operating Margin

Return on Assets (ttm)

-39.5

Return on Equity (ttm)

-43.0

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-1.262

Qtrly Earnings Growth

Operating Cash Flow (M)

Levered Free Cash Flow (M)

atoplab.com

Valuation

P/E

-11.46

P/E Growth Ratio

-0.01

P/BV

4.81

P/S

P/CF

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.